Tevogen Bio Holdings Inc. TVGN 深 滬
已收盤 01-09 16:00:00 美东时间
0.389
-0.001
-0.26%
華盛通- 最 高0.417
- 今 開0.40
- 成交量 213.30万股
- 最 低 0.3705
- 昨 收 0.39
- 總市值 7741.10万
- 52周最高 1.92
- 市盈率 靜 --
- 換手率 1.07%
- 52周最低 0.299
- 委 比 -96.20%
- 總股本 1.99亿
- 歷史最高 21.09
- 量 比 4.17
- 振 幅 11.92%
- 歷史最低 0.2556
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
2025-11-28 17:49
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $10 to $5.
2025-11-20 21:13
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility
This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489
2025-11-06 04:22
Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings.GAAP
2025-11-04 03:55
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Bio Holdings Inc. has reaffirmed its commitment to sustainable and affordable precision medicine, focusing on accessible and scalable T cell therapies. The company highlighted progress in its ExacTcell platform with TVGN 489, addressing Long COVID and other conditions, and shared financial projections of $9–$11 billion rNPV and $6.5 billion in revenue for liver cancer prevention. Tevogen.AI advanced its PredicTcell model with Microsoft an...
2025-10-29 16:35
Tevogen Intends To Collaborate With Government Initiatives, Long COVID Patient Organizations, And Major Healthcare Providers To Expedite Development Of TVGN 489; Establishes A Dedicated Communication Channel For Long COVID Updates At longCOVID@tevogen.com
Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries,
2025-10-16 03:52
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
TevogenBio Holdings Inc. announced updates on its investigational therapy TVGN 489 for COVID-19 and Long COVID, highlighting strong patient interest. The company plans to collaborate with government initiatives, patient organizations, and healthcare providers to advance development. A dedicated email channel, longCOVID@tevogen.com, has been created to share updates.
2025-10-15 19:50
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Tevogen's PredicTcell™ platform, developed with Microsoft and Databricks, has expanded its training dataset to ~1.4 million and total dataset to over 6.7 billion records. This significant increase aims to enhance precision in identifying virology targets, potentially making T-cell therapies nearly 100% accurate. The expansion includes analyzing over 10.7 billion data points and increasing model features from 22 to 27. These advancements could rev...
2025-09-25 12:30
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen highlights emerging evidence linking persistent viral reservoirs to Long COVID and presents its investigational precision T cell therapy, TVGN 489, as a potential treatment. Studies show residual SARS-CoV-2 proteins and RNA persist long after infection, contributing to chronic inflammation and Long COVID symptoms. TVGN 489, targeting multiple SARS-CoV-2 proteins, demonstrated efficacy in reducing viral load and maintaining CTL persistence...
2025-09-23 12:30
